The generic drug market in Central Europe is not uniform, even though the individual countries in the region operate within the European Union’s single market or are strongly influenced by European regulations. The availability of treatments is determined not only by product registration, but also by how reimbursement is determined, the structure of reference prices, the level of patient copayments, and the purchasing practices of pharmacies and wholesalers.

For manufacturers, distributors, investors, and public institutions, comparing these mechanisms is of strategic importance. It allows one to identify where price pressure is greatest, what barriers limit a product’s market entry, and which factors increase the risk of a drug being unavailable at pharmacies. In a regional analysis, it is also important to distinguish between formal reimbursement rules and the actual experience of patients and pharmacists.

Why is a comparison of Central European markets important?

Central Europe comprises markets with similar growth potential but differing healthcare financing systems. Poland, the Czech Republic, Slovakia, Hungary, Romania, and Bulgaria employ various tools to control public spending on medications. The common thread is the payers’ drive to reduce treatment costs, especially after the patent protection for brand-name products expires.

Generic drugs are a key instrument of drug policy in this model. Price competition can facilitate the financing of a greater number of therapies, but excessive pressure on prices can also lead to supply issues. A product may be formally reimbursed yet still unavailable at a specific pharmacy if commercial conditions do not ensure the profitability of its distribution.

A comparison of countries in the region should therefore simultaneously include:

• the rules for including drugs in the reimbursement program;
• methods for setting funding limits and reference prices;
• the scope of copayments borne by patients;
• rules for pharmacy substitution;
• conditions for wholesale and retail distribution;
• the risk of shortages and product withdrawals from the market.

How does reimbursement affect the position of generic drugs?

Reimbursement is not merely a decision on whether a drug will be partially or fully funded by public funds. It is also a mechanism that defines the conditions of competition among products containing the same active ingredient or deemed comparable within a given reimbursement group. In many reimbursement systems, a generic drug is evaluated within a group corresponding to a specific active ingredient or a reference group defined by the payer.

If reimbursement is tied to a funding cap, a patient may receive the drug at no additional cost or may have to pay the difference between the product’s retail price and the established cap. In practice, therefore, it is not only inclusion on the reimbursement list that matters, but also the relationship between the price of a given formulation and the reference price.

How do reimbursement models differ across the region?

In Poland, the reimbursement mechanism is based, among other things, on limit groups and official prices for products covered by public funding. The system promotes price competition but requires manufacturers to constantly monitor changes to reimbursement lists, administrative decisions, and the actions of competitors within the same group.

The Czech Republic and Slovakia also use reference-based mechanisms, though local rules governing reimbursement levels, patient copayments, and product classification play a significant role. In the Czech Republic, an annual protective cap on selected patient copayments plays a significant role, and the market is characterized by intense competition among generic products.

In Hungary, pricing and reimbursement policies remain closely tied to public expenditure control. For companies, this means the need to assess not only the entry price but also the sustainability of the revenue model in the face of potential regulatory adjustments. In Romania and Bulgaria, an additional challenge may be the market’s greater sensitivity to budget constraints, payment delays, or significant discrepancies between the formal scope of reimbursement and the actual availability of products.

How do reference prices and funding limits work?

A reference price serves as a benchmark for reimbursing products deemed comparable. It may be determined based on the price of the cheapest drug in the group, a specific market price level, or administrative rules adopted by the payer. The structure of this mechanism determines what portion of the treatment cost will be covered by public funds.

For the patient, the reference system is usually visible as a copayment at the pharmacy. For the manufacturer, however, it means having to make pricing decisions that take into account competitors’ behavior, margins in the distribution chain, and the likely reaction of the public payer.

Why doesn’t the lowest price always mean the best strategy?

Aggressively lowering the price can improve a product’s position within the reimbursement group and increase its appeal to patients. At the same time, it can reduce profitability to a level that limits the ability to maintain inventory, serve the pharmacy channel, or ensure stable supplies. The risk increases particularly for products with low unit value and high sensitivity to logistics costs.

In countries where the domestic price is analyzed in relation to prices in other jurisdictions, a decision made in one market may affect pricing options in subsequent countries. For this reason, a strategy for Central Europe should take into account the sequence of market entry, the potential impact of cross-border prices, and the risk of parallel exports of products.

Before submitting a price offer, it is advisable to verify:

• the rules for forming reference groups;
• the frequency of updates to reimbursement limits;
• the pricing positions of current competitors;
• the scope of patient copayments for individual products;
• margin conditions for wholesalers and pharmacies;
• the risk that a price reduction could affect other export markets.

What determines a drug’s availability at a pharmacy?

The availability of a drug at a pharmacy should be understood more broadly than simply its inclusion in the reimbursement catalog. A patient needs a drug that is physically available, in the appropriate dosage, form, and package size, and at an acceptable price. Even a well-designed reimbursement system does not eliminate the problem if the product is periodically unavailable from wholesalers or if the pharmacy does not keep it in its regular inventory.

Availability is influenced by wholesalers’ purchasing decisions, inventory turnover, transportation temperature requirements, order predictability, and the manufacturer’s ability to secure supply. Communication with pharmacists is also important, as they can, within the limits of local regulations, offer patients an equivalent product that is currently available.

What role does pharmacy substitution play?

Pharmacy substitution can increase the use of generic drugs if patients receive clear information about available equivalents and any difference in copayment. However, the effectiveness of this approach depends on national regulations, the pharmacist’s authority, patient habits, and trust in generic products.

In some Central European markets, greater emphasis is placed on the pharmacist’s active role in selecting a reimbursed product. In others, the decision remains more closely tied to the specific brand indicated on the prescription or to the physician’s preferences. When analyzing sales potential, it is therefore necessary to examine not only reimbursement data but also the actual decision-making process in the doctor’s office and at the pharmacy.

How should a market comparison be prepared for a manufacturer or investor?

A reliable regional analysis should combine regulatory, economic, and operational perspectives. A review of reimbursement lists alone is insufficient, as it does not reveal the actual dynamics of substitution, the strength of competition, or the risk of supply issues. It is essential to combine public data with information obtained from market participants.

PMR Market Experts publishes periodic industry reports that can serve as a starting point for assessing trends, market structure, and the competitive landscape. When planning activities across multiple countries, it is also helpful to use dedicated analyses, such as an analysis of the generic and innovative drug markets in Central Europe.

In Polish analyses, research conducted by independent research agencies, such as Hume’s Institute, can be helpful, especially when it is necessary to understand patient behavior, physicians’ opinions, or pharmacists’ experiences. Qualitative data should be cross-referenced with reimbursement, sales, and distribution information.

What questions should you ask before entering the market?

Before launching sales, it is worth determining whether the product has a real price advantage, how long it can maintain that advantage, and whether availability in pharmacies will be supported by an appropriate logistics model. It is also worth checking whether the selected therapeutic category is particularly susceptible to substitution and whether patients accept switching brands.

In practice, market entry decisions should be based on scenarios rather than on a single pricing option. Market forecasts that take into account potential regulatory changes, competitor actions, and the development of distribution channels are helpful in this regard. For projects requiring the adaptation of a commercial model to local conditions, strategic consulting based on sector-specific data is also useful.

Key Findings

Generic drug markets in Central Europe share a strong role for reimbursement and price controls, but differ in how limits are set, the extent of patient copayments, and the practice of pharmacy substitution. An effective strategy cannot be mechanically copied from one country to another.

• Reimbursement sets the terms of competition but does not guarantee product availability at the pharmacy;
• the reference price influences patient copayments and purchasing decisions throughout the distribution chain;
• the lowest price may increase volume but also limit supply stability;
• regional analysis requires the integration of regulatory, commercial, and qualitative data;
• A local understanding of the behavior of physicians, pharmacists, and patients is crucial.

If your goal is to assess the potential of generic drugs in Central Europe, develop a pricing strategy, or compare reimbursement mechanisms, contact PMR Market Experts to base your decisions on up-to-date market data and a practical analysis of local conditions.